Annual Report 2025
Annual Report 2025
Tim Van Hauwermeiren
Chief Executive Officer
Peter Verhaeghe
Chairman of the Board
Tim Van Hauwermeiren
Chief Executive Officer
Peter Verhaeghe
Chairman of the Board
Message to Our Shareholders
2025 was a remarkable year of execution, grounded in our urgent commitment to deliver meaningful innovation for patients. We delivered across our strategic priorities and continued to make meaningful progress toward our Vision 2030 goal of reaching 50,000 patients – strengthening the core of our business while advancing the science that will define our future.
We treated 19,000 patients globally with VYVGART, and we successfully launched the VYVGART HYTRULO pre-filled syringe in gMG and CIDP, continuing to drive new patient and prescriber demand while underscoring the trust we believe physicians place in our medicine.
Read the Shareholder Letter
We hear you
Each day at argenx, we are motivated to pursue a better tomorrow alongside patients. We aim to do this through partnership because we know that "together we are better". As your ally, we pioneer innovations to advance the understanding of rare diseases; we want to deliver immunology treatments to patients worldwide.
Read our stories
Financial highlights
Explore 2025 in Brief2026 Outlook
2026 marks a defining year on the path to Vision 2030 with three strategic priorities:
- Impact more patients globally with VYVGART, driving broader adoption across current patient populations and unlocking new opportunities with potential label expansions
- Shape the long-term future of FcRn medicines, advancing future FcRn molecules, innovative delivery modalities and combination approaches designed to transform patient outcomes
- Deliver next wave of immunology innovation, accelerating empasiprubart and diversified pipeline of first-in-class molecules to drive sustainable value creation